HOME >> MEDICINE >> NEWS
Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers

Orqis Medical Corp. today announced that the U.S. Food and Drug Administration has approved an expansion of the Cancion CRSTM clinical trial from eight to 40 medical centers nationwide, accelerating the trial's recruitment and enrollment efforts.

The Cancion CRS therapy is a percutaneous cardiac recovery system being studied for its ability to create a "rest-to-recovery" environment for congestive heart failure (CHF) patients. Enrollment in the Multicenter trial of the Orqis Medical CRS for the ENhanced Treatment of CHF, Unresponsive to Medical Therapy (MOMENTUM) trial began in September of this year.

"We've worked with the FDA to develop an effective protocol for the MOMENTUM trial and are gratified that we can now ramp up to a full complement of sites," said Marvin A. Konstam, M.D., Medical Director of Orqis Medical and Chief of Cardiology at Tufts-New England Medical Center in Boston. "This puts us yet another step closer to our goal of documenting the value that the Cancion therapy can bring to patients with heart failure."

Heart failure is the deterioration of the heart's ability to pump blood throughout the body and adequately perfuse the major organs. According to the AHA, some five million Americans have heart failure and an additional 550,000 are diagnosed annually. The single most expensive diagnosis in the U.S. health care system, acutely decompensated heart failure, represents 1 million primary and 2.5 million secondary hospital admissions annually.

About The Cancion CRS Therapy
A breakthrough discovery in hemodynamics -- the simple supplementation of blood flow specifically in the descending aorta -- led to the development of the Cancion CRS therapy, which centers on the novel use of a blood pump and proprietary peripheral access to the circulatory system.

The Cancion CRS increases blood flow in the descending aorta without t
'"/>

Contact: Kimberly Goolsby
kimberly@goolsbygroup.com
949-464-0187
Goolsby Group
10-Jan-2005


Page: 1 2

Related medicine news :

1. New data on Orqis Medicals Cancion CRS to be reported at ACC
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
10. Pfizers antifungal medicine VFEND receives FDA approval
11. Shire receives US FDA approval of EQUETRO (TM) for bipolar disorder

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/17/2018)... , ... October 17, 2018 , ... ... Prisoner Health and Human Rights identifies best practices in the management of lesbian, ... report notes that LGBT youth are overrepresented in the juvenile justice system, especially ...
(Date:10/16/2018)... , ... October 16, 2018 , ... ... in small business loans, equipment leasing, and franchise financing , is now ... the United States. Balboa Capital will structure and deliver custom-tailored financing programs to ...
(Date:10/16/2018)... ... October 16, 2018 , ... Intrinsic released ... easy-to-use software for biopharma companies. By pairing the InTime time tracker with Intrinsic’s ... questions without spending millions of dollars implementing a complicated enterprise project management tool ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... an attorney experienced in employment law, writes frequently on employment law matters and ... authored a chapter in the Health Care Compliance Professional's Manual titled “Navigating the ...
(Date:10/16/2018)... ... October 16, 2018 , ... AutismOne, the nation’s largest ... of the 4th Annual International HPV Vaccine Education Symposium. , Presenters from countries ... 2019, through Friday, May 24, 2019, with a keynote address from Robert F. ...
Breaking Medicine News(10 mins):
(Date:10/16/2018)... ... , ... Ripple Massage, Australia’s leading mobile massage company, has added ... foot soaks to its packages. , “Ripple is much more than a mobile massage ... want all the pampering extras when they book a massage with us that can ...
(Date:10/16/2018)... ... 2018 , ... The iaedp™ Foundation, recognized for excellence in ... providers who treat the full spectrum of eating disorder problems, will once again ... at Symposium 2019. The courses are regularly offered in a self-paced, online ...
(Date:10/13/2018)... ... 2018 , ... David Young was the inventor of US ... Lockheed F22 Aircraft. Today, he announces the invention of the Two-Dimensional Arrhythmia Monitor ... sudden cardiac death (SCD). , The Two-Dimensional Arrhythmia Monitor has the potential to ...
Breaking Medicine Technology:
Cached News: